Trending...
- READY FOR NEW BUILDS – Pond & Waterfall Construction Season Starts Now!
- Generic Trade Marks 15 Years of Leveling the Trading Field for all Futures Traders
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
~ A new study has found that once-weekly insulin efsitora alfa (efsitora) is just as effective as daily basal insulin in lowering blood glucose levels in people with type 2 diabetes. The results of the QWINT-1 study were presented at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and published simultaneously in The New England Journal of Medicine.
The study, which was the first of its kind, aimed to address the growing need for simpler options for insulin therapy. According to the findings, one in four people with type 2 diabetes do not take their prescribed dosage of basal insulin correctly due to the burden of daily injections and frequent dose adjustments. This can lead to dangerous high blood glucose levels and long-term organ damage.
QWINT-1 was a Phase 3, open-label, randomized study that evaluated the efficacy and safety of a fixed-dose titration of once-weekly insulin efsitora in 795 adults with type 2 diabetes who were taking basal insulin for the first time. The study compared efsitora to once-daily insulin glargine, with the goal of determining whether a fixed-dose, once-weekly regimen could offer comparable blood glucose management while reducing the burden of starting and managing insulin therapy. Efsitora was titrated to four fixed doses at four-week intervals as needed for blood glucose management.
More on illi News
After 52 weeks, the study showed that efsitora lowered A1C levels by 1.31%, reaching an average A1C of 6.92%, compared to a reduction of 1.27% and an A1C of 6.96% with insulin glargine. A second analysis based on how well patients followed their treatment also showed similar results: efsitora reduced A1C by 1.19% (to 7.05%) compared to a reduction of 1.16% (to 7.08%) with glargine.
Lead investigator of the QWINT-1 trial, Dr. Julio Rosenstock, senior scientific advisor at Medical City Dallas and clinical professor of medicine at the University of Texas Southwestern Medical Center, stated that these results confirm the effectiveness of once-weekly insulin efsitora in controlling blood sugar levels while also offering the benefit of a simpler dosing schedule. He also noted that the novel fixed-dose regimen used in the study has the potential to ease the burden of starting insulin therapy for both patients and providers, potentially improving adherence and long-term health outcomes.
More on illi News
In light of these findings, Lilly has announced plans to submit efsitora for the treatment of type 2 diabetes to global regulatory authorities by the end of 2025.
The results of this study were presented by Dr. Rosenstock at a symposium titled "Advancing and Facilitating Basal Insulin Therapy in Type 2 Diabetes—Breaking News on the QWINT 1, 3, and 4 Trials with Once-Weekly Insulin Efsitora Alfa!" on Sunday, June 22 at 2:20 p.m. CT. The presentation focused on the efficacy and safety of efsitora as a weekly basal insulin using a novel fixed-dose escalation compared to insulin glargine in insulin-naïve participants with type 2 diabetes.
This groundbreaking study offers hope for people with type 2 diabetes who struggle with daily injections and dose adjustments for basal insulin therapy. With once-weekly insulin efsitora showing comparable results to daily basal insulin, it has the potential to simplify treatment and improve long-term health outcomes for patients.
The study, which was the first of its kind, aimed to address the growing need for simpler options for insulin therapy. According to the findings, one in four people with type 2 diabetes do not take their prescribed dosage of basal insulin correctly due to the burden of daily injections and frequent dose adjustments. This can lead to dangerous high blood glucose levels and long-term organ damage.
QWINT-1 was a Phase 3, open-label, randomized study that evaluated the efficacy and safety of a fixed-dose titration of once-weekly insulin efsitora in 795 adults with type 2 diabetes who were taking basal insulin for the first time. The study compared efsitora to once-daily insulin glargine, with the goal of determining whether a fixed-dose, once-weekly regimen could offer comparable blood glucose management while reducing the burden of starting and managing insulin therapy. Efsitora was titrated to four fixed doses at four-week intervals as needed for blood glucose management.
More on illi News
- $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
- Chicago: Mayor Johnson, City Officials Honor 1995 Heat Wave Victims, Forgotten WWII Hero Emilio Aguirre with Full Military Funeral Honors
- $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
- Disposable Vape Ban Spurs Hayati Innovation
- Prolific Hollywood "Unknown Actor" Leads 11 Day SoCal, Hands-On, Performer Employment Securing Residency that Shows Others How to Get More Work
After 52 weeks, the study showed that efsitora lowered A1C levels by 1.31%, reaching an average A1C of 6.92%, compared to a reduction of 1.27% and an A1C of 6.96% with insulin glargine. A second analysis based on how well patients followed their treatment also showed similar results: efsitora reduced A1C by 1.19% (to 7.05%) compared to a reduction of 1.16% (to 7.08%) with glargine.
Lead investigator of the QWINT-1 trial, Dr. Julio Rosenstock, senior scientific advisor at Medical City Dallas and clinical professor of medicine at the University of Texas Southwestern Medical Center, stated that these results confirm the effectiveness of once-weekly insulin efsitora in controlling blood sugar levels while also offering the benefit of a simpler dosing schedule. He also noted that the novel fixed-dose regimen used in the study has the potential to ease the burden of starting insulin therapy for both patients and providers, potentially improving adherence and long-term health outcomes.
More on illi News
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
- Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
- Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
- Samyang Corporation Unveils 'AI-Based Standardized Sugar Reduction Solution' at US Food Technology Expo
- Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
In light of these findings, Lilly has announced plans to submit efsitora for the treatment of type 2 diabetes to global regulatory authorities by the end of 2025.
The results of this study were presented by Dr. Rosenstock at a symposium titled "Advancing and Facilitating Basal Insulin Therapy in Type 2 Diabetes—Breaking News on the QWINT 1, 3, and 4 Trials with Once-Weekly Insulin Efsitora Alfa!" on Sunday, June 22 at 2:20 p.m. CT. The presentation focused on the efficacy and safety of efsitora as a weekly basal insulin using a novel fixed-dose escalation compared to insulin glargine in insulin-naïve participants with type 2 diabetes.
This groundbreaking study offers hope for people with type 2 diabetes who struggle with daily injections and dose adjustments for basal insulin therapy. With once-weekly insulin efsitora showing comparable results to daily basal insulin, it has the potential to simplify treatment and improve long-term health outcomes for patients.
Filed Under: Business
0 Comments
Latest on illi News
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- AI Maturity Emerges as Key Driver of ROI, New Protiviti Study Finds
- Premier Custom Hardwood Flooring Launches New Website to Better Serve Homeowners and Businesses in the NW Chicago Suburbs
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- WIOA-Funded Seats Still Available for Summer Product-Owner Training
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- Entyre Solutions Launches to Support Senior Living Operators
- Jungbunzlauer Launches New TayaGel® LA at IFT First 2025, strengthening its texturants portfolio USA - English USA - English USA - Français Japan - Japanese USA - Deutsch
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Eliza Nevius Reimagines a Classic with a Dark, Witty Twist in The Key to Wonderland
- Naperville Police Initiate Death Investigation
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Mayor Johnson Appoints Era Patterson As Executive Director Of The Chicago Office Of Public Safety Administration